Starlight Therapeutics Forms Scientific Advisory Board for STAR-001
Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), has taken a monumental step in advancing its initiatives by establishing a Scientific Advisory Board (SAB). This newly formed board is designed to support and provide expert guidance for the development of STAR-001, a novel compound aimed at treating central nervous system cancers, including brain tumors, in both children and adults.
The Role of the Scientific Advisory Board
The inaugural SAB is set to collaborate closely with the management team at Starlight Therapeutics, contributing strategic insights and expert advice throughout the development process of STAR-001. Dr. Marc Chamberlain, M.D., Starlight's Chief Medical Officer, expressed tremendous optimism about the board, stating that the members bring remarkable subject matter expertise. With the inclusion of esteemed professionals like Drs. Berger, DeAngelis, Grossman, and Laterra, the board is poised to shape the clinical path for STAR-001 effectively.
Meet the Members of the SAB
The Scientific Advisory Board consists of numerous distinguished experts recognized for their contributions to oncology and neurology. Below is a brief overview of each member:
Dr. Mitchel S. Berger, M.D.
Dr. Berger is a prominent figure in neurosurgery, serving as chair of the Department of Neurosurgery and director of the Brain Tumor Center at UCSF. His expertise includes treating brain and spinal cord tumors, focusing on brain mapping and noninvasive radiation techniques such as Gamma Knife.
Dr. Lisa M. DeAngelis, M.D.
As the Chief Physician Executive at Memorial Sloan Kettering Cancer Center, Dr. DeAngelis oversees a wide array of clinical services and research. Her acclaimed research focuses on neurological complications of cancer treatment and she has authored numerous peer-reviewed publications, marking her as a leading voice in brain cancer treatment.
Dr. Stuart Grossman, M.D.
A Professor of Oncology at the Johns Hopkins Kimmel Cancer Center, Dr. Grossman has been instrumental in directing clinical and research neuro-oncology efforts. His vast experience includes leadership roles in multiple collaborative brain cancer research projects nationally.
Dr. John Laterra, MD, Ph.D.
Dr. Laterra is celebrated for his research on brain tumor malignancy and therapeutic targets in gliomas. As Co-Director of the Brain Cancer Disease Group at Johns Hopkins, he is at the forefront of identifying innovative treatments for malignant brain tumors.
Importance of STAR-001
The STAR-001 program represents a significant development in the landscape of CNS cancer therapy. This unique small molecule is designed to penetrate the blood-brain barrier effectively, utilizing a mechanism of action based on synthetic lethality that targets DNA damage repair deficiencies prevalent in CNS cancers. The compelling evidence supporting STAR-001's potential has been showcased across numerous scientific forums, and it may become the first new therapy for treating glioblastoma multiforme (GBM) since 2003.
Starlight Therapeutics has conducted extensive research validating the efficacy of STAR-001 across various animal models, including those for GBM and other challenging CNS malignancies. As research continues to advance, the SAB will play a pivotal role in guiding the trajectory of STAR-001's development—potentially transforming the treatment landscape for patients facing CNS tumors.
About Starlight Therapeutics
Starlight Therapeutics is committed to pioneering advancements in CNS cancer treatments. With its focus on STAR-001, the company employs advanced mechanisms of action to exploit vulnerabilities within cancer cells, demonstrating promise through significant preclinical success.
Frequently Asked Questions
What is the purpose of the Scientific Advisory Board?
The SAB provides strategic guidance and expert insights for the development of STAR-001, aimed at treating CNS cancers.
Who are the notable members of the SAB?
The SAB includes renowned experts such as Drs. Berger, DeAngelis, Grossman, and Laterra, each with extensive backgrounds in oncology and neurosurgery.
What is STAR-001?
STAR-001 is a small molecule that targets DNA damage repair deficiencies in CNS cancers, with the potential to be a groundbreaking treatment for conditions like GBM.
Why is STAR-001 significant?
It may become the first new drug for GBM since 2003, representing a major breakthrough in CNS cancer therapy.
How can I learn more about Starlight Therapeutics?
Interested individuals can visit Starlight Therapeutics’ official website for additional information on their research and development efforts.
